MPG.eBooks - Search Results - "Insurance, Health, Reimbursement"

Cover Image

1

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

2

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

3

CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

4

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

5

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

6

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

7

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

8

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

9

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement / economics...”

Cover Image

10

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement / economics...”

Cover Image

11

CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)

Published 2020

CADTH

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

12

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”

Cover Image

13

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Health, Reimbursement...”